Michael Barbella, Managing Editor04.28.21
Strong growth is predicted for the global scaffold technology market by the end of the decade.
A new study from Polaris Market Research forecasts a 9.1 percent annual growth rate over the next seven years and a market value of $2.2 billion in 2028.
Recent advancements in micro-molding, photo-lithography, and stereo-lithography are driving scaffolding technology. For instance, the innovations in injectable and microporous hydrogels have enabled organ on a chip technology to enhance in-vivo healing. Moreover, ongoing advancements in micro-fabrication technology are also projected to boost the market growth.
In 2020, the hydrogels market segment of scaffold technology industry had the largest revenue share. This high share is attributed to the excellent properties of hydrogels, such as controlled drug delivery, and ease of loading drugs. In current times, hydrogels have gained momentum and are regarded as a leading candidate in 3D cell cultures and tissue engineering.
The nanofiber scaffolds segment is projected to show the fastest growth rate over the assessment period. Nanoscale fibrous structures with inter-connecting pores facilitate the formation of artificial tissues during the process of tissue engineering. Artificial tissues resemble natural ones, by providing an extracellular matrix of the living tissues.
Market participants such as Merck KGaA; Molecular Matrix; Pelobiotech; Corning Incorporated; Avacta Life Sciences Limited; Vericel Corporation; Becton, Dickinson and Company; 3D Biotek LLC; Thermo Fisher Scientific; Xanofi; REPROCELL Inc.; Matricel GmbH; Akron Biotech; Nanofiber Solutions; 4titude; 3D BioMatrix; NuVasive Inc.; Allergan; and Medtronic plc are some of the key players operating in the global market for scaffold technology.
Players in the marketplace are collaborating with small players to stay competitive in the market for scaffold technology. For instance, in October 2019, Avacta Life Sciences collaborated with ADC Therapeutics to develop Affimer drug conjugates for use in biological scaffolds.
A new study from Polaris Market Research forecasts a 9.1 percent annual growth rate over the next seven years and a market value of $2.2 billion in 2028.
Recent advancements in micro-molding, photo-lithography, and stereo-lithography are driving scaffolding technology. For instance, the innovations in injectable and microporous hydrogels have enabled organ on a chip technology to enhance in-vivo healing. Moreover, ongoing advancements in micro-fabrication technology are also projected to boost the market growth.
In 2020, the hydrogels market segment of scaffold technology industry had the largest revenue share. This high share is attributed to the excellent properties of hydrogels, such as controlled drug delivery, and ease of loading drugs. In current times, hydrogels have gained momentum and are regarded as a leading candidate in 3D cell cultures and tissue engineering.
The nanofiber scaffolds segment is projected to show the fastest growth rate over the assessment period. Nanoscale fibrous structures with inter-connecting pores facilitate the formation of artificial tissues during the process of tissue engineering. Artificial tissues resemble natural ones, by providing an extracellular matrix of the living tissues.
Market participants such as Merck KGaA; Molecular Matrix; Pelobiotech; Corning Incorporated; Avacta Life Sciences Limited; Vericel Corporation; Becton, Dickinson and Company; 3D Biotek LLC; Thermo Fisher Scientific; Xanofi; REPROCELL Inc.; Matricel GmbH; Akron Biotech; Nanofiber Solutions; 4titude; 3D BioMatrix; NuVasive Inc.; Allergan; and Medtronic plc are some of the key players operating in the global market for scaffold technology.
Players in the marketplace are collaborating with small players to stay competitive in the market for scaffold technology. For instance, in October 2019, Avacta Life Sciences collaborated with ADC Therapeutics to develop Affimer drug conjugates for use in biological scaffolds.